CoChat

BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression

Murphy, Greer M., Sarginson, Jane E., Ryan, Heather S., O’Hara, Ruth, Schatzberg, Alan F., Lazzeroni, Laura C. · 2013 · Pharmacogenetics and Genomics

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

AIM: Brain-derived neurotrophic factor (BDNF) is associated with antidepressant response on the cellular level, in animal models, and in clinical studies. A common variant in the BDNF gene results in a substitution of a methionine (Met) for a valine at the amino acid position 66. Previous studies reported that the Met variant results in enhanced response to antidepressant medications. These findings may be at odds with studies indicating that on a cellular level the Met variant impairs the secretion of BDNF. MATERIALS AND METHODS: We examined the effects of BDNF single nucleotide polymorphisms (SNPs) in response to the antidepressants paroxetine and mirtazapine in a sample of 246 geriatric patients with major depression, treated in a double-blind, randomized, 8-week clinical trial. We also examined the effects of genetic variation at the BDNF-related loci neurotrophic tyrosine kinase receptor 2, cyclic AMP responsive element binding protein 1 (CREB1), and CREB binding protein. A total of 53 SNPs were genotyped. RESULTS: BDNF genetic variation had a significant effect on the efficacy of paroxetine, with patients carrying the Met allele showing impaired response. SNPs at the CREB1 locus, which encodes a transcription factor important in BDNF signaling, also predicted response to paroxetine. Furthermore, we found a significant gene-gene interaction between BDNF and CREB1 that affected response to paroxetine. Because BDNF has been associated with cognitive function, we tested the effects of BDNF SNPs on change in a wide variety of cognitive tests over the 8-week trial, but there were no significant effects of genotype on cognition. CONCLUSION: These results provide new evidence for the importance of the BDNF pathway in antidepressant response in geriatric patients. The negative effect of the Met66 allele on antidepressant outcomes is consistent with basic science findings indicating a negative effect of this variant on BDNF activity in the brain. Further, the effect of BDNF genetic variation on antidepressant treatment is modified by variation in the gene encoding the downstream effector CREB1.

Overview

Integrity signals

Registry

Crossref · 10.1097/fpc.0b013e328360b175

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 56 references

Cited by

See all 50

Metadata

Authors
Murphy, G. M., Sarginson, J. E., Ryan, H. S., O’Hara, R., Schatzberg, A. F., & Lazzeroni, L. C.
Affiliations
Stanford Medicine (US)
Corresponding author
Murphy, Greer M.
Venue
Pharmacogenetics and Genomics
Published
2013-06
Volume
23
Issue
6
Pages
301-313
ISSN
1744-6872 (ISSN-L)
OpenAlex
W2056261919
Cited by
50
References
56
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 7 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 2
FWCI
4.65
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacogenetics and Genomics (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (R01MH073914, MH-47573, R01MH050604, MH073914-04S1, MH073914, MH50604, R01MH086135, R01MH047573)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
brain-derived neurotrophic factor, CREB1, geriatric depression, major depressive disorder, antidepressant response, paroxetine, mirtazapine, gene-gene interaction, single nucleotide polymorphisms, CREB-binding protein, cognitive function, pharmacogenetics
MeSH terms
Aged, Alleles, Antidepressive Agents, Depression, Female, Gene Frequency, Haplotypes, Humans, Male, Models, Genetic, Linkage Disequilibrium, Likelihood Functions, Treatment Outcome, Cyclic AMP Response Element-Binding Protein, Brain-Derived Neurotrophic Factor, Polymorphism, Single Nucleotide, Principal Component Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.